Search

Zehra Kaymakcalan

from Westborough, MA
Age ~71
Get Report
Also known as:
Zemra Kaymakcalan, Sehra Kaymakcalan, Kaymakcalan Zehra, Zehra N
Phone and address:
4 Piccadilly Way, Westboro, MA 01581
(508) 366-3977
Related to:
Mark L Dusevic, 79
Connected to:
Berkay Kaymak, 36Sungur A Kaymak, 69Lindsay A Kaymen, 35Shamika L Kaymore, 40Naci Kaynak, 67Jeyda D Kaynatma, 31Anastacia H Kayne, 36Marybeth Kayne, 61Ronald C Kayne, 86Sharlene A Kayne, 64

Zehra Kaymakcalan Phones & Addresses

  • 4 Piccadilly Way, Westborough, MA 01581 (508) 366-3977 (508) 366-5968
  • San Francisco, CA
  • Malvern, PA
  • Berwyn, PA
  • Southborough, MA
  • El Cerrito, CA
  • Mountain View, CA
  • 4 Piccadilly Way, Westborough, MA 01581 (508) 353-3163

Work

Company: Abbvie 2013 Position: Research fellow

Education

School / High School: University of California, San Francisco - School of Medicine Jan 1, 1978 to Dec 31, 1983

Skills

Monoclonal Antibodies • Drug Discovery • Biotechnology • Pharmaceutical Industry • Biomarkers • Drug Development • Lifesciences • Clinical Development • Antibodies • Immunology • Biologics • Clinical Trials • Biopharmaceuticals • Assay Development • In Vitro

Industries

Pharmaceuticals

Resumes

Resumes

Zehra Kaymakcalan Photo 1

Research Fellow

View page
Location:
4 Piccadilly Way, Westborough, MA 01581
Industry:
Pharmaceuticals
Work:
Abbvie
Research Fellow
Abbott
Senior Principal Scientist
Centocor 1992 - 1994
Senior Scientist
Cetus 1986 - 1992
Scientist
Bristol-Myers Squibb 1983 - 1986
Post-Doctoral Fellow
Education:
University of California, San Francisco - School of Medicine Jan 1, 1978 - Dec 31, 1983
Skills:
Monoclonal Antibodies
Drug Discovery
Biotechnology
Pharmaceutical Industry
Biomarkers
Drug Development
Lifesciences
Clinical Development
Antibodies
Immunology
Biologics
Clinical Trials
Biopharmaceuticals
Assay Development
In Vitro

Business Records

Name / Title
Company / Classification
Phones & Addresses
Zehra Kaymakcalan
Vice president
ORHAN GUNDUZ MEMORIAL SCHOOL, INC
Elementary/Secondary School
1 Presidential Dr, Southborough, MA 01772
Westborough, MA 01581

Publications

Us Patents

Human Antibodies That Bind Human Tnfa

View page
US Patent:
6509015, Jan 21, 2003
Filed:
Mar 31, 2000
Appl. No.:
09/540018
Inventors:
Jochen G. Salfeld - North Grafton MA
Deborah J. Allen - London, GB
Hendricus R. J. M. Hoogenboom - Hasselt, BE
Zehra Kaymakcalan - Westboro MA
Boris Labkovsky - Framingham MA
John A. Mankovich - Andover MA
Brian T. McGuinness - Cambridge, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Shrewsbury MA
David Schoenhaut - Clifton NJ
Tristan J. Vaughan - Cambridge, GB
Michael White - Framingham MA
Alison J. Wilton - Cambridge, GB
Assignee:
BASF Aktiengesellschaft - Ludwigshafen
International Classification:
A61K 39395
US Classification:
4241421, 424 852, 4241451, 424800, 424810
Abstract:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor (hTNF) are disclosed. These antibodies have high affinity for hTNF (e. g. , K =10 M or less), a slow off rate for hTNF dissociation (e. g. , K =10 sec or less) and neutralize hTNF activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF and for inhibiting hTNF activity, e. g. , in a human subject suffering from a disorder in which hTNF activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human Antibodies That Bind Human Il-12 And Methods For Producing

View page
US Patent:
6914128, Jul 5, 2005
Filed:
Mar 24, 2000
Appl. No.:
09/534717
Inventors:
Jochen Salfeld - North Grafton MA, US
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Shrewsbury MA, US
Daniel Tracey - Harvard MA, US
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Melrose MA, US
Nicholas W. Warne - Andover MA, US
Angela Myles - Andover MA, US
John Gawain Elvin - Cambridge, GB
Alexander Robert Duncan - Little Shelford, GB
Elaine Joy Derbyshire - Royston, GB
Sara Carmen - Cambridge, GB
Thor Las Holtet - Royston, GB
Sarah Leila Du Fou - Hitchen, GB
Stephen Smith - Ely, GB
Assignee:
Abbott GmbH & Co. KG - Wiesbaden
International Classification:
C07K016/18
C07K016/24
C12P021/08
US Classification:
5303873, 5303871, 5303879, 53038815, 53038824, 5303892, 530351
Abstract:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e. g. , in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human Antibodies That Bind Human Tnfα

View page
US Patent:
7223394, May 29, 2007
Filed:
Mar 7, 2001
Appl. No.:
09/801185
Inventors:
Jochen G. Salfeld - North Grafton MA, US
Deborah J. Allen - Cambridge, GB
Hendricus R. J. M. Hoogenboom - Maastricht, BE
Zehra Kaymakcalan - Westboro MA, US
Boris Labkovsky - Framingham MA, US
John A. Mankovich - Andover MA, US
Brian T. McGuinness - Comberton, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Newton MA, US
David Schoenhaut - Garfield NJ, US
Tristan J. Vaughan - Impington, GB
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge, GB
Assignee:
Abbott Biotechnology Ltd - Hamilton
International Classification:
A61K 39/395
US Classification:
4241421, 4241451, 4241581, 53038815, 53038823, 5303892
Abstract:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e. g. , K=10M or less), a slow off rate for hTNFα dissociation (e. g. , K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e. g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Dual Specificity Antibodies And Methods Of Making And Using

View page
US Patent:
7491516, Feb 17, 2009
Filed:
Jun 28, 2001
Appl. No.:
09/894550
Inventors:
Albert Collinson - Marlboro MA, US
George Avgerinos - Sudbury MA, US
Richard Dixon - North Grafton MA, US
Tariq Ghayur - Holliston MA, US
Zehra Kaymakcalan - Westboro MA, US
Assignee:
Abbott Laboratories - Abbott Park IL
International Classification:
C12P 21/08
C12P 21/04
C07K 16/00
A61K 39/00
A61K 39/395
US Classification:
435 7021, 53038823, 4241301, 4241411, 4241421, 4241451
Abstract:
Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1α and IL-1β and neutralize IL-1α and IL-1β activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e. g. , IL-1α and IL-1β ) and for inhibiting the activity of the antigens, e. g. , in a human subject suffering from a disorder in which IL-1α and/or IL-1β activity is detrimental.

Human Antibodies That Bind Human Il-12

View page
US Patent:
7504485, Mar 17, 2009
Filed:
Jul 1, 2004
Appl. No.:
10/884830
Inventors:
Jochen G. Salfeld - North Grafton MA, US
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Shrewsbury MA, US
Daniel Edward Tracey - Harvard MA, US
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Cary NC, US
Nicholas W. Warne - Andover MA, US
Angela Myles - Andover MA, US
John Gawain Elvin - Cambridge, GB
Alexander Robert Duncan - Cambridge, GB
Elaine J. Derbyshire - Royston, GB
Sara Carmen - Cambridge, GB
Stephen Smith - Ely, GB
Thor Las Holtet - Royston, GB
Sarah Leila Du Fou - Hitchen, GB
Assignee:
Abbott GmbH & Co., KG - Wiesbaden
International Classification:
C07K 16/24
A61K 39/395
US Classification:
53038823, 4241451
Abstract:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e. g. , in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Methods For Treating Rheumatoid Arthritis Using Human Antibodies That Bind Human Tnfα

View page
US Patent:
7541031, Jun 2, 2009
Filed:
Apr 17, 2007
Appl. No.:
11/787901
Inventors:
Jochen G. Salfeld - North Grafton MA, US
Deborah J. Allen - London, GB
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
John A. Mankovich - Andover MA, US
Brian T. McGuinness - Cambridge, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Newton Highlands MA, US
Hendricus R. J. M. Hoogenboom - Hasselt, BE
David Schoenhaut - Clifton NJ, US
Tristan J. Vaughan - Cambridge, GB
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge, GB
Assignee:
Abbott Biotechnology Ltd.
International Classification:
A61K 39/395
A61K 31/495
US Classification:
4241421, 4241451, 4241581, 424810, 514249
Abstract:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e. g. , K=10M or less), a slow off rate for hTNFα dissociation (e. g. , K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e. g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human Antibodies That Bind Human Tnfα

View page
US Patent:
7588761, Sep 15, 2009
Filed:
Sep 21, 2005
Appl. No.:
11/233252
Inventors:
Jochen G. Salfeld - North Grafton MA, US
Deborah J. Allen - London, GB
Hendricus R. J. M. Hoogenboom - Hasselt, BE
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
John A. Mankovich - Andover MA, US
Brian T. McGuinness - Cambridge, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Newton MA, US
David Schoenhaut - Clifton NJ, US
Tristan J. Vaughan - Cambridge, GB
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge MA, US
Assignee:
Abbott Biotechnology Ltd. - Hamilton
International Classification:
A61K 39/395
C07K 16/24
US Classification:
4241421, 4241451, 4241581, 424484, 424486, 424810, 53038815, 53038823, 530868
Abstract:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e. g. , K=10M or less), a slow off rate for hTNFα dissociation (e. g. , K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e. g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Methods For Inhibiting The Activity Of The P40 Subunit Of Human Il-12

View page
US Patent:
7883704, Feb 8, 2011
Filed:
Dec 22, 2006
Appl. No.:
11/645287
Inventors:
Jochen G. Salfeld - North Grafton MA, US
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Hamden CT, US
Daniel Edward Tracey - Harvard MA, US
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton Highlands MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Cary NC, US
Nicholas W. Warne - Andover MA, US
Angela Kantor - Pepperell MA, US
John Gawain Elvin - Meldreth, GB
Alexander Robert Duncan - Carton, GB
Elaine Joy Derbyshire - Crowthorne, GB
Sara Carmen - Cambridge, GB
Stephen Smith - Ely, GB
Thor Las Holtet - Rønde, DK
Sarah Leila Du Fou - Hitchen, GB
Assignee:
Abbott GmbH & Co. KG - Wiesbaden
International Classification:
A61K 38/20
A61K 39/395
C07K 16/24
C12P 21/08
US Classification:
4241451, 53038823, 5303881, 5303891, 514 14, 4241301
Abstract:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12 ) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e. g. , in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Control profile
Zehra Kaymakcalan from Westborough, MA, age ~71 Get Report